Overview
- The scientific guideline adds recent therapies and is accompanied by a new patient guideline that translates recommendations into plain language.
- Atogepant, a CGRP-receptor–targeting drug, is now approved for migraine prevention and features in the updated recommendations.
- Remote electrical neuromodulation gains a place as a non-drug option, approved from age 12, though it is not yet an insured benefit.
- Experts highlight the central role of CGRP, with monoclonal antibodies halving monthly migraine days in more than half of treated patients and showing low reported side effects.
- Migraine affects up to 15% of people in Germany and about one billion worldwide, remains without a cure, and pediatric services report long waits and gaps in care.